Nadja Prang

1.5k total citations
23 papers, 1.2k citations indexed

About

Nadja Prang is a scholar working on Oncology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Nadja Prang has authored 23 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 9 papers in Immunology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Nadja Prang's work include Viral-associated cancers and disorders (13 papers), Lymphoma Diagnosis and Treatment (7 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Nadja Prang is often cited by papers focused on Viral-associated cancers and disorders (13 papers), Lymphoma Diagnosis and Treatment (7 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Nadja Prang collaborates with scholars based in Germany, Austria and Switzerland. Nadja Prang's co-authors include Patrick A. Baeuerle, Fritz Schwarzmann, Hans Wolf, Klaus Brischwein, Christian Brandl, Ralf C. Bargou, Robert Hofmeister, Michael Jäger, Christian Itin and Patrick Hoffmann and has published in prestigious journals such as Blood, Journal of Virology and British Journal of Cancer.

In The Last Decade

Nadja Prang

22 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nadja Prang Germany	17	837	448	376	269	234	23	1.2k
Achim Rothe Germany	21	763 0.9×	693 1.5×	476 1.3×	469 1.7×	493 2.1×	41	1.7k
John O. Richards United States	16	477 0.6×	638 1.4×	370 1.0×	423 1.6×	87 0.4×	32	1.4k
G. Reisbach Germany	16	511 0.6×	458 1.0×	123 0.3×	258 1.0×	174 0.7×	26	1.1k
E Tatsumi Japan	21	612 0.7×	685 1.5×	185 0.5×	639 2.4×	506 2.2×	82	1.8k
Silvio Roncella Italy	24	621 0.7×	651 1.5×	150 0.4×	524 1.9×	615 2.6×	87	1.9k
Carsten Reinhardt Germany	15	1.0k 1.2×	723 1.6×	655 1.7×	454 1.7×	200 0.9×	37	1.7k
Marcus Odendahl Germany	19	622 0.7×	1.8k 4.1×	417 1.1×	260 1.0×	140 0.6×	33	2.6k
M. Schaadt Germany	19	571 0.7×	809 1.8×	404 1.1×	449 1.7×	928 4.0×	46	1.9k
Giorgio Inghirami United States	16	401 0.5×	640 1.4×	303 0.8×	231 0.9×	308 1.3×	28	1.3k
L. Bronz Switzerland	9	417 0.5×	538 1.2×	70 0.2×	213 0.8×	194 0.8×	21	1.3k

Countries citing papers authored by Nadja Prang

Since Specialization

Citations

This map shows the geographic impact of Nadja Prang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nadja Prang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nadja Prang more than expected).

Fields of papers citing papers by Nadja Prang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nadja Prang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nadja Prang. The network helps show where Nadja Prang may publish in the future.

Co-authorship network of co-authors of Nadja Prang

This figure shows the co-authorship network connecting the top 25 collaborators of Nadja Prang. A scholar is included among the top collaborators of Nadja Prang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nadja Prang. Nadja Prang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brandl, Christian, Nadja Prang, Ralf Lutterbuese, et al.. (2008). Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leukemia Research. 33(3). 465–473. 58 indexed citations

Weckermann, Dorothea, Alfred Zippelius, A. Schoberth, et al.. (2007). A multimarker real-time RT-PCR for MAGE-A gene expression allows sensitive detection and quantification of the minimal systemic tumor load in patients with localized cancer. Journal of Immunological Methods. 323(2). 180–193. 12 indexed citations

Brandl, Christian, Cornelia Haas, Tanja Fisch, et al.. (2007). The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunology Immunotherapy. 56(10). 1551–1563. 103 indexed citations

Weckermann, Dorothea, Cornelia Quadt, Tobias Raum, et al.. (2006). A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. European Journal of Cancer. 42(15). 2530–2538. 38 indexed citations

Breuhahn, Kai, Patrick A. Baeuerle, Mark Peters, et al.. (2005). Expression of epithelial cellular adhesion molecule (Ep-CAM) in chronic (necro-)inflammatory liver diseases and hepatocellular carcinoma. Hepatology Research. 34(1). 50–56. 20 indexed citations

Schlereth, Bernd, Cornelia Quadt, Torsten Dreier, et al.. (2005). T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunology Immunotherapy. 55(5). 503–514. 77 indexed citations

Prang, Nadja, et al.. (2005). Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. British Journal of Cancer. 92(2). 342–349. 123 indexed citations

Locher, Mathias, et al.. (2005). High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Molecular Immunology. 43(8). 1183–1193. 100 indexed citations

Hoffmann, Patrick, Robert Hofmeister, Klaus Brischwein, et al.. (2005). Serial killing of tumor cells by cytotoxic T cells redirected with a CD19‐/CD3‐bispecific single‐chain antibody construct. International Journal of Cancer. 115(1). 98–104. 264 indexed citations

10.

Kufer, Peter, Alfred Zippelius, Ralf Lutterbüse, et al.. (2002). Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease.. PubMed. 62(1). 251–61. 64 indexed citations

11.

Babel, Nina, Fritz Schwarzmann, Nadja Prang, et al.. (2001). ASSOCIATION BETWEEN EPSTEIN-BARR VIRUS INFECTION AND LATE ACUTE TRANSPLANT REJECTION IN LONG-TERM TRANSPLANT PATIENTS1. Transplantation. 72(4). 736–739. 31 indexed citations

12.

Prang, Nadja, Hans Wolf, & Fritz Schwarzmann. (1999). Latency of Epstein-Barr virus is stabilized by antisense-mediated control of the viral immediate-early gene BZLF-1. Journal of Medical Virology. 59(4). 512–519. 13 indexed citations

13.

Jäger, Michael, Nadja Prang, Bakary S. Sylla, et al.. (1998). Epstein-Barr virus-infected B cells of males with the X-linked lymphoproliferative syndrome stimulate and are susceptible to T-cell-mediated lysis. International Journal of Cancer. 76(5). 694–701. 12 indexed citations

14.

Schwarzmann, Fritz, Michael Jäger, Mathias W. Hornef, Nadja Prang, & Hans Wolf. (1998). Epstein-Barr Viral Gene Expression in B-Lymphocytes. Leukemia & lymphoma. 30(1-2). 123–129. 14 indexed citations

15.

Prang, Nadja, Mathias W. Hornef, Michael Jäger, et al.. (1997). Lytic Replication of Epstein-Barr Virus in the Peripheral Blood: Analysis of Viral Gene Expression in B Lymphocytes During Infectious Mononucleosis and in the Normal Carrier State. Blood. 89(5). 1665–1677. 57 indexed citations

16.

Prang, Nadja, Manfred Mitterer, Clara Larcher, et al.. (1996). Pathogenesis of chronic Epstein‐Barr virus infection: detection of a virus strain with a high rate of lytic replication. British Journal of Haematology. 95(4). 626–636. 12 indexed citations

17.

Larcher, Clara, Falko Fend, Manfred Mitterer, et al.. (1995). Role of Epstein‐Barr virus and soluble CD21 in persistent polyclonal B‐cell lymphocytosis. British Journal of Haematology. 90(3). 532–540. 22 indexed citations

18.

Mitterer, Manfred, Norbert Pescosta, Falko Fend, et al.. (1995). Chronic active Epstein‐Barr virus disease in a case of persistent polyclonal B‐cell lymphocytosis. British Journal of Haematology. 90(3). 526–531. 24 indexed citations

19.

Prang, Nadja, Hans Wolf, & Fritz Schwarzmann. (1995). Epstein-Barr virus lytic replication is controlled by posttranscriptional negative regulation of BZLF1. Journal of Virology. 69(4). 2644–2648. 25 indexed citations

20.

Prang, Nadja, Udo Reischl, R. Arndt, et al.. (1994). Identification of Epstein-Barr virus transactivator BZLF1 mRNA in uncultured peripheral blood lymphocytes by RT-polymerase chain reaction. Cellular and Molecular Life Sciences. 50(9). 796–796.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact